開示情報 > SanBio’s US-based phase 1/2a clinical trial of SB623 was addressed at an event held by California Institute for Regenerative Medicine (CIRM)

SanBio’s US-based phase 1/2a clinical trial of SB623 was addressed at an event held by California Institute for Regenerative Medicine (CIRM)

SanBio’s US-based phase 1/2a clinical trial of SB623 was addressed at an event held by California Institute for Regenerative Medicine (CIRM)

開示者 【45920】サンバイオ株式会社
文書名 SanBio’s US-based phase 1/2a clinical trial of SB623 was addressed at an event held by California Institute for Regenerative Medicine (CIRM)  
PDF/XBRL [別ウインドウでPDFを開く]
開示日時 2018/06/15 チャネル/カテゴリ 東京証券取引所 /その他
ノート ログインするとIR文書にメモを入力して管理することができます
右上のログインメニューからログインしてください。


開示情報 > SanBio’s US-based phase 1/2a clinical trial of SB623 was addressed at an event held by California Institute for Regenerative Medicine (CIRM)